ArticleJournal of translational medicine2026
Tet2 deficiency drives age-related heterogeneous progression of myeloid neoplasms through epigenetic-immune microenvironment imbalance.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTet2 dysfunction drives myeloid neoplasm initiation and progression, yet the mechanisms underlying disease heterogeneity, age-dependent progression and immune microenvironment perturbation remain poorly understood. This study aimed to establish a hematopoietic specific Tet2 conditional knockout mouse model to elucidate these core mechanisms and recapitulate clinical features of Tet2 mutated myeloid neoplasms.
methodsWe generated Mx1-Cre-mediated haematopoietic-specific Tet2 conditional knockout mice on a C57BL/6JGpt background using CRISPR-Cas9 and Cre-LoxP technologies. Haematopoietic phenotypes, pathological features and immune microenvironment dynamics were systematically characterised in 5- and 12-month-old mice, with wild-type littermates as controls. Statistical analyses were applied for intergroup comparisons of phenotypic and immunological indices.
resultsTet2 deficiency induced myeloid neoplasms with distinct age-dependent progression. Five-month-old mice exhibited mild hematological abnormalities without overt pathology, whereas 12-month-old mice developed typical myeloid neoplasm phenotypes including pancytopenia, splenomegaly, myelodysplasia, with heterogeneous subtypes spanning myelodysplastic syndrome, myeloproliferative neoplasm and acute myeloid leukemia. These mice were also accompanied by severe immune dysregulation. Mechanistically, Tet2-deficient bone marrow established an immunosuppressive niche characterised by M2-like macrophage polarisation and a skewed CCR4 ligand profile with elevated CCL22 and diminished CCL17, which selectively recruited Foxp3⁺ regulatory T cells. Concurrently, serum cytokine profiling revealed broad immune activation spanning Th1-type, Th2-type and Th17-type responses. Male mice exhibited significantly accelerated disease progression compared with females.
conclusionsTet2 deficiency drives myeloid neoplasm progression through the synergy of epigenetic dysregulation, age-related hematopoietic stem cell damage and immune microenvironment imbalance. This model recapitulates core clinical features of elderly Tet2-mutated myeloid neoplasms and provides a preclinical platform for mechanistic investigation and the development of epigenetic and immune-targeted precision therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.